Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $90.00 by Analysts at Truist Financial

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price cut by Truist Financial from $100.00 to $90.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on RARE. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Wells Fargo & Company assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday, October 20th. They issued an “overweight” rating and a $65.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Morgan Stanley lowered their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, July 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.75.

Ultragenyx Pharmaceutical Stock Down 1.8%

NASDAQ RARE opened at $31.87 on Wednesday. The company’s 50 day moving average is $31.44 and its 200-day moving average is $32.90. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $53.47. The firm has a market cap of $3.07 billion, a P/E ratio of -5.76 and a beta of 0.30.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. During the same period last year, the firm earned ($1.40) EPS. The business’s revenue for the quarter was up 14.6% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. This represents a 3.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,942 shares of the stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at $3,095,132.77. The trade was a 7.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 10,456 shares of company stock worth $328,486 in the last ninety days. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares during the last quarter. WCM Investment Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 36.9% in the 3rd quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company’s stock worth $8,747,000 after buying an additional 77,640 shares during the last quarter. Privium Fund Management B.V. increased its holdings in shares of Ultragenyx Pharmaceutical by 14.4% in the 3rd quarter. Privium Fund Management B.V. now owns 289,804 shares of the biopharmaceutical company’s stock worth $8,717,000 after buying an additional 36,500 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Ultragenyx Pharmaceutical by 2.2% in the 3rd quarter. Arizona State Retirement System now owns 25,176 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 533 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Ultragenyx Pharmaceutical by 31.1% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 67,834 shares of the biopharmaceutical company’s stock worth $2,040,000 after buying an additional 16,096 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.